Latanoprostene bunod
Clinical data | |
---|---|
Trade names | Vyzulta |
Other names | BOL-303259-X |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.251.571 |
Chemical and physical data | |
Formula | C27H41NO8 |
Molar mass | 507.624 g·mol−1 |
3D model (JSmol) | |
| |
|
Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1]
References
- ^ "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension" (Press release). Valeant Pharmaceuticals International, Inc.